1. Scrip
  2. >>Business
  3. >>Strategy

External R&D Is Up, But Which Companies Are Reaping The Most Benefit?

 
• By Joseph Haas

Amgen, Novartis and Lilly are projected to increase sales from externally sourced assets in the coming years, according to a Datamonitor Healthcare analysis, while other big pharma – including frequent acquirer Pfizer and smaller-deal-oriented Bristol – are expected to see that ratio decline compared to sales of internally developed drugs.

External sourcing of pipeline assets is increasing overall within big pharma, but there is significant variation among the sector's companies, according to a new report from Datamonitor Healthcare. Amgen Inc., Novartis AG and Eli Lilly & Co. are expected to experience the most significant increases in externally sourced product sales, while such revenue is expected to decline sharply at Bristol-Myers Squibb Co., Bayer AG, Merck & Co. Inc. and Pfizer Inc.

The Pharma Externalization Strategies 2016: Externalization Is Critical to Pharma Revenue report, published Sept. 13, notes that co-developed and acquired...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Activist Investor Vs. Japan Pharma: ASKA Plans Poison Pill As Dalton Pushes For MBO

 
• By Lisa Takagi

While ASKA tries to double the number of its stocks to avoid MBO attempts by Dalton, the Asia-focused PE insists on the plan while criticising the move as irresponsible.

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By Joseph Haas

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

More from Business

Stock Watch: Pharma Financial Forecasts Cannot Withstand Headwinds Forever

 
• By Andy Smith

Pharma company financial guidance emerged largely unscathed from a first quarter punctured by a weakening US dollar and threats of import tariffs on drugs. With other pressures either already evident or on the horizon, guidance revisions may be unavoidable.

Q2 Korea Biotech Roundup: Licensing Deals End, Trials Progress, IPOs Recover

 
• By Jung Won Shin

Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.